Ionis Pharmaceuticals (IONS) – Press Releases
-
Ionis Publishes 2023 Corporate Responsibility Report
-
Ionis to hold first quarter 2024 financial results webcast
-
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
-
Ionis to present at upcoming investor conferences
-
Ionis to hold olezarsen Phase 3 data webcast
-
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
-
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
-
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
-
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
-
Ionis to present at upcoming investor conferences
-
Ionis reports fourth quarter and full year 2023 financial results
-
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
-
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
-
Ionis to hold fourth quarter and full year 2023 financial results webcast
-
Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
-
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
-
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
-
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
-
Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen)
-
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
-
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
-
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
-
Ionis announces the appointment of Michael Yang to Board of Directors
-
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
-
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
-
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
-
Ionis to present at upcoming investor conferences
-
Ionis reports third quarter 2023 financial results
-
Ionis to hold third quarter 2023 financial results webcast
-
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
-
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
-
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
-
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
-
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
-
Ionis to host investor and analyst day event
-
Ionis to present at upcoming investor conferences
-
Ionis reports second quarter 2023 financial results
-
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
-
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
-
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
-
Ionis to hold second quarter 2023 financial results webcast
-
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
-
Ionis to present at upcoming investor conference
-
New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
-
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
-
Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen)
-
Ionis prices private placement of convertible senior notes
-
Ionis announces proposed private placement of convertible notes
-
Ionis announces positive donidalorsen late-stage clinical progress in HAE
-
Ionis to host 2023 virtual Annual Meeting of Stockholders
Back to IONS Stock Lookup
